Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study ...

Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...

Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

Eli Lilly (LLY) has recently shared positive developments in its innovative therapies, reporting significant progress with ...

Kisunla, a newly approved Alzheimer's drug in Taiwan, would not be covered by the National Health Insurance (NHI) system, ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Eli Lilly & Company (NYSE:LLY) ranks among the best non-tech stocks to buy according to billionaires. Eli Lilly & Company ...

Eli Lilly has cleared a major hurdle in its bid to win European approval for its Alzheimer's disease drug Kisunla.

The FDA greenlit multiple new drugs this month and issued some notable label expansions including for Eli Lilly’s Kisunla.

Kisunla comes as a liquid solution that’s given as an IV infusion (an injection into your vein over a period of time). Your doctor or another healthcare professional will give you the infusions.

European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.